Insider Selling: Progyny (NASDAQ:PGNY) COO Sells 9,578 Shares of Stock

Progyny, Inc. (NASDAQ:PGNY) COO Melissa Cummings sold 9,578 shares of the company’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $25.00, for a total value of $239,450.00. Following the completion of the sale, the chief operating officer directly owned 73,371 shares in the company, valued at $1,834,275. This trade represents a 11.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Stock Down 3.7%

Shares of PGNY traded down $0.95 during trading hours on Thursday, reaching $24.69. 1,424,301 shares of the company traded hands, compared to its average volume of 1,560,195. The stock has a market capitalization of $1.93 billion, a PE ratio of 32.06, a price-to-earnings-growth ratio of 1.31 and a beta of 0.91. Progyny, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $28.75. The stock has a fifty day simple moving average of $18.78 and a 200 day simple moving average of $21.97.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.03. The business had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The business’s revenue for the quarter was down 26.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Research analysts predict that Progyny, Inc. will post 1.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PGNY has been the topic of a number of analyst reports. JPMorgan Chase & Co. set a $35.00 price objective on Progyny in a research note on Wednesday, January 21st. Zacks Research upgraded Progyny from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. Canaccord Genuity Group upgraded Progyny from a “hold” rating to a “buy” rating and increased their target price for the stock from $19.00 to $30.00 in a research report on Tuesday. Finally, Citigroup reiterated an “outperform” rating on shares of Progyny in a research report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Progyny currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.55.

Hedge Funds Weigh In On Progyny

Several large investors have recently added to or reduced their stakes in PGNY. Caitong International Asset Management Co. Ltd purchased a new position in Progyny during the fourth quarter worth about $25,000. Federated Hermes Inc. raised its holdings in shares of Progyny by 147.3% in the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock worth $30,000 after purchasing an additional 819 shares during the period. Hantz Financial Services Inc. raised its holdings in shares of Progyny by 79.4% in the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after purchasing an additional 742 shares during the period. Covestor Ltd raised its holdings in shares of Progyny by 164.9% in the 3rd quarter. Covestor Ltd now owns 2,609 shares of the company’s stock worth $56,000 after purchasing an additional 1,624 shares during the period. Finally, Quarry LP raised its holdings in shares of Progyny by 2,004.1% in the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after purchasing an additional 3,427 shares during the period. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.